Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes-Reference-Cited by-同舟云学术

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes

Published:2014-11-14 Issue:3 Volume:75 Page:280-291
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Yan Lisa¹²,Silva Diane M. Da²³,Verma Bhavna²,Gray Andrew²⁴,Brand Heike E.²,Skeate Joseph G.¹²,Porras Tania B.¹²,Kanodia Shreya²⁵,Kast W. Martin¹²³⁶

Affiliation:

1. Department of Molecular Microbiology and Immunology; University of Southern California; Los Angeles California

2. Norris Comprehensive Cancer Center; University of Southern California; Los Angeles California

3. Department of Obstetrics and Gynecology; University of Southern California; Los Angeles California

4. Vali Nanomedical LLC; Los Angeles California

5. Samuel Oschin Comprehensive Cancer Institute and Department of Biomedical Sciences; Cedars-Sinai Medical Center; Los Angeles California

6. Department of Urology; University of Southern California; Los Angeles California

Funder

U.S. Department of Defense

National Institutes of Health

Publisher

Wiley

Subject

Urology,Oncology

Reference48 articles.

1. http://seer.cancer.gov/csr/1975_2011/

2. Biology of castration-recurrent prostate cancer;Azzouni;Urol Clin North Am,2012

3. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells;Zhang;Prostate,2013

4. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer;Yin;Int J Mol Sci,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients;Seminars in Immunology;2023-09

2. Soluble LIGHT (TNFSF14) activates endothelial cells, thereby priming the first vessel-occlusive events in acute sickle cell disease;2023-06-08

3. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas;Frontiers in Immunology;2022-10-20

4. Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations;Cancers;2022-06-22

5. Current strategies in engaging oncolytic viruses with antitumor immunity;Molecular Therapy - Oncolytics;2021-09